Conference Call with Indoco Remedies Ltd. Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Indoco Remedies announced Q4FY23 & FY23 results: Q4FY23: During Q4FY23, revenues grew by 6.9% at Rs 428.0 crore, as against Rs 400.3 crore in Q4FY22 EBIDTA to net sales for Q4FY23 is 15.0% at Rs 64.2 crore, compared to 20.1% at Rs 80.5 crore in Q4FY22 For Q4FY23, the Profit After Tax is at Rs 25.4 crore, compared to Rs 40.4 crore in Q4FY22 Profit After Tax with other comprehensive income is at Rs 29.7 crore, compared to Rs 35.6 crore in Q4FY22 FY23: For FY23, the revenues grew by 9.0% at Rs 1,638.1 crore, as against Rs 1,502.7 crore in FY22 EBIDTA to net sales for FY23 is 17.4% at Rs 284.9 crore, compared to 21.8% at Rs 327.0 crore in FY22 For FY23, the Profit After Tax is at Rs 141.4 crore, compared to Rs 154.5 crore in FY22 Profit After Tax with other comprehensive income is at Rs 142.8 crore, compared to Rs 149.2 crore in FY22 Commenting on the results, Aditi Panandikar, Managing Director, Indoco Remedies said, “Our performance this year is a function of a predictable performance of India business, free of COVID impact, accompanied by a good performance of Export business”. Result PDF
Conference Call with Indoco Remedies Management and Analysts on Q3FY23 Performance and Outlook. Listen to the full earnings transcript.